NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $4.85 +0.33 (+7.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.55▼$4.9250-Day Range$4.34▼$6.5852-Week Range$3.66▼$8.90Volume540,279 shsAverage Volume629,310 shsMarket Capitalization$467.47 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alector alerts: Email Address Alector MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside202.4% Upside$14.67 Price TargetShort InterestHealthy4.85% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment0.42Based on 10 Articles This WeekInsider TradingSelling Shares$286,013 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.92) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector112th out of 910 stocksBiological Products, Except Diagnostic Industry15th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAlector has only been the subject of 2 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.85% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Alector has recently decreased by 10.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 2.5 News and Social Media Coverage News SentimentAlector has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Alector this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ALEC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows3 people have added Alector to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $286,013.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($1.92) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Alector Stock (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALEC Stock News HeadlinesSeptember 5 at 7:27 AM | insidertrades.comMarc Grasso Sells 7,297 Shares of Alector, Inc. (NASDAQ:ALEC) StockAugust 14, 2024 | insidertrades.comPaula Hammond Sells 10,500 Shares of Alector, Inc. (NASDAQ:ALEC) StockSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 6 at 8:07 AM | americanbankingnews.comSara Kenkare-Mitra Sells 13,926 Shares of Alector, Inc. (NASDAQ:ALEC) StockSeptember 6 at 6:13 AM | americanbankingnews.comArnon Rosenthal Sells 26,499 Shares of Alector, Inc. (NASDAQ:ALEC) StockSeptember 3, 2024 | americanbankingnews.comAlector, Inc. (NASDAQ:ALEC) Sees Significant Decrease in Short InterestAugust 29, 2024 | globenewswire.comAlector to Participate in Upcoming Healthcare ConferencesAugust 13, 2024 | markets.businessinsider.comAlector’s Strong Outlook: Advancing Pipeline and Undervalued Stock Prompt Buy RatingSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 9, 2024 | seekingalpha.comAlector, Inc. (ALEC) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finance.yahoo.comAlector Second Quarter 2024 Earnings: Beats ExpectationsAugust 8, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating on Alector Amid Promising Biomarker Research and Positive FDA InteractionsAugust 7, 2024 | finance.yahoo.comAlector Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 5, 2024 | finance.yahoo.comABBV Aug 2024 162.500 call (ABBV240809C00162500)July 31, 2024 | globenewswire.comAlector to Host Mid-Year Earnings Conference CallJuly 28, 2024 | globenewswire.comAlector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)July 23, 2024 | globenewswire.comAlector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024July 12, 2024 | seekingalpha.comAlector: Brain Science Play With High Expenses And Few CatalystsSee More Headlines Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Stock Price Target$14.67 High Stock Price Target$35.00 Low Stock Price Target$4.00 Potential Upside/Downside+202.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,390,000.00 Net Margins-290.66% Pretax Margin-285.24% Return on Equity-102.63% Return on Assets-25.70% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio3.52 Sales & Book Value Annual Sales$55.28 million Price / Sales8.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book3.13Miscellaneous Outstanding Shares96,385,000Free Float87,614,000Market Cap$467.47 million OptionableOptionable Beta0.68 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Arnon Rosenthal Ph.D. (Age 68)Co-Founder, CEO & Director Comp: $1.02MDr. Sara Kenkare-Mitra Ph.D. (Age 56)President and Head of Research & Development Comp: $1.19MDr. Marc Grasso M.D. (Age 50)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $738.05kDr. Gary Romano M.D. (Age 62)Ph.D., Chief Medical Officer Comp: $602.98kMr. Peter Heutink Ph.D.Chief Scientific OfficerKatie HoganSenior Director of Corporate Communication & Investor RelationsMs. Danielle Pasqualone J.D.Ph.D., General CounselMs. Clare Hunt M.B.A.Chief People OfficerMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerMs. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of StrategyMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSC4 TherapeuticsNASDAQ:CCCCNantKwestNASDAQ:NKREGENXBIONASDAQ:RGNXBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsArnon RosenthalSold 26,499 sharesTotal: $129,315.12 ($4.88/share)Sara Kenkare-MitraSold 13,926 sharesTotal: $67,958.88 ($4.88/share)Marc GrassoSold 7,297 sharesTotal: $35,609.36 ($4.88/share)Truist Financial CorpSold 5,820 shares on 8/21/2024Ownership: 0.035%Point72 Asset Management L.P.Sold 80,915 shares on 8/19/2024Ownership: 0.637%View All Insider TransactionsView All Institutional Transactions ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $7.98 at the beginning of the year. Since then, ALEC shares have decreased by 39.2% and is now trading at $4.85. View the best growth stocks for 2024 here. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. The company earned $15.08 million during the quarter, compared to analyst estimates of $16.04 million. Alector had a negative trailing twelve-month return on equity of 102.63% and a negative net margin of 290.66%. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Does Alector have any subsidiaries? Alector subsidiaries include Alector LLC. When did Alector IPO? Alector (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. Who are Alector's major shareholders? Top institutional investors of Alector include Deerfield Management Company L.P. Series C (1.19%), Dimensional Fund Advisors LP (0.70%), Renaissance Technologies LLC (0.68%) and Point72 Asset Management L.P. (0.64%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Robert King, Sara Kenkare-Mitra, Gary Romano, Marc Grasso, Paula Hammond and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO) and QUALCOMM (QCOM). This page (NASDAQ:ALEC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALEC Stock Alerts